{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:39:13Z","timestamp":1771457953776,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s11657-020-0702-2","type":"journal-article","created":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:02:43Z","timestamp":1588989763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bisphosphonate utilization across the spectrum of eGFR"],"prefix":"10.1007","volume":"15","author":[{"given":"Silvia M.","family":"Titan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Laureati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex R.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan E.","family":"Grams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"issue":"11","key":"702_CR1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29(11):2520\u20132526. https:\/\/doi.org\/10.1002\/jbmr.2269","journal-title":"J Bone Miner Res"},{"issue":"7041","key":"702_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254\u20131259. https:\/\/doi.org\/10.1136\/bmj.312.7041.1254","journal-title":"BMJ"},{"issue":"8837","key":"702_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","volume":"341","author":"SR Cummings","year":"1993","unstructured":"Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993) Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group. Lancet 341(8837):72\u201375. https:\/\/doi.org\/10.1016\/0140-6736(93)92555-8","journal-title":"Lancet"},{"issue":"10","key":"702_CR4","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381. https:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"702_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"issue":"12","key":"702_CR6","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"issue":"6","key":"702_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152(6):380\u2013390. https:\/\/doi.org\/10.7326\/0003-4819-152-6-201003160-00008","journal-title":"Ann Intern Med"},{"issue":"3","key":"702_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/joim.12586","volume":"281","author":"M Katsoulis","year":"2017","unstructured":"Katsoulis M, Benetou V, Karapetyan T, Feskanich D, Grodstein F, Pettersson-Kymmer U, Eriksson S, Wilsgaard T, Jorgensen L, Ahmed LA, Schottker B, Brenner H, Bellavia A, Wolk A, Kubinova R, Stegeman B, Bobak M, Boffetta P, Trichopoulou A (2017) Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med 281(3):300\u2013310. https:\/\/doi.org\/10.1111\/joim.12586","journal-title":"J Intern Med"},{"issue":"7","key":"702_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, Ross SD (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14(7):570\u2013576. https:\/\/doi.org\/10.1007\/s00198-003-1435-y","journal-title":"Osteoporos Int"},{"issue":"1","key":"702_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58(1):396\u2013399. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00178.x","journal-title":"Kidney Int"},{"issue":"1","key":"702_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1681\/asn.2006050546","volume":"18","author":"LF Fried","year":"2007","unstructured":"Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18(1):282\u2013286. https:\/\/doi.org\/10.1681\/asn.2006050546","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"702_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167(2):133\u2013139. https:\/\/doi.org\/10.1001\/archinte.167.2.133","journal-title":"Arch Intern Med"},{"key":"702_CR13","doi-asserted-by":"publisher","unstructured":"Runesson B, Trevisan M, Iseri K, Qureshi AR, Lindholm B, Barany P, Elinder CG, Carrero JJ (2019) Fractures and their sequelae in non-dialysis-dependent chronic kidney disease: the Stockholm CREAtinine measurements project. Nephrol Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfz142","DOI":"10.1093\/ndt\/gfz142"},{"issue":"4","key":"702_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/sdi.12388","volume":"28","author":"SM Ott","year":"2015","unstructured":"Ott SM (2015) Pharmacology of bisphosphonates in patients with chronic kidney disease. Semin Dial 28(4):363\u2013369. https:\/\/doi.org\/10.1111\/sdi.12388","journal-title":"Semin Dial"},{"issue":"3","key":"702_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1525-139X.2007.00271.x","volume":"20","author":"PD Miller","year":"2007","unstructured":"Miller PD (2007) Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 20(3):186\u2013190. https:\/\/doi.org\/10.1111\/j.1525-139X.2007.00271.x","journal-title":"Semin Dial"},{"issue":"1","key":"702_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, Moe SM, Shroff R, Tonelli MA, Toussaint ND, Vervloet MG, Leonard MB (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int 92(1):26\u201336. https:\/\/doi.org\/10.1016\/j.kint.2017.04.006","journal-title":"Kidney Int"},{"key":"702_CR17","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures."},{"issue":"2","key":"702_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jsps.2017.12.005","volume":"26","author":"B Balkhi","year":"2018","unstructured":"Balkhi B, Seoane-Vazquez E, Rodriguez-Monguio R (2018) Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharm J 26(2):238\u2013243. https:\/\/doi.org\/10.1016\/j.jsps.2017.12.005","journal-title":"Saudi Pharm J"},{"issue":"1","key":"702_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ckj\/sfv117","volume":"9","author":"B Runesson","year":"2016","unstructured":"Runesson B, Gasparini A, Qureshi AR, Norin O, Evans M, Barany P, Wettermark B, Elinder CG, Carrero JJ (2016) The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness. Clin Kidney J 9(1):119\u2013127. https:\/\/doi.org\/10.1093\/ckj\/sfv117","journal-title":"Clin Kidney J"},{"issue":"9","key":"702_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"9731","key":"702_CR21","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375(9731):2073\u20132081. https:\/\/doi.org\/10.1016\/s0140-6736(10)60674-5","journal-title":"Lancet"},{"issue":"1","key":"702_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2010.531","volume":"80","author":"RT Gansevoort","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J (2011) Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80(1):93\u2013104. https:\/\/doi.org\/10.1038\/ki.2010.531","journal-title":"Kidney Int"},{"issue":"6","key":"702_CR23","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00198-019-04872-4","volume":"30","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Nilsson AG, Johansson H, Kanis JA, Mellstrom D, Sundh D (2019) Extensive undertreatment of osteoporosis in older Swedish women. Osteoporos Int 30(6):1297\u20131305. https:\/\/doi.org\/10.1007\/s00198-019-04872-4","journal-title":"Osteoporos Int"},{"issue":"1","key":"702_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00198-006-0206-y","volume":"18","author":"B Haussler","year":"2007","unstructured":"Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D (2007) Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study. Osteoporos Int 18(1):77\u201384. https:\/\/doi.org\/10.1007\/s00198-006-0206-y","journal-title":"Osteoporos Int"},{"issue":"2","key":"702_CR25","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00198-004-1680-8","volume":"16","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2005) Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 16(2):134\u2013141. https:\/\/doi.org\/10.1007\/s00198-004-1680-8","journal-title":"Osteoporos Int"},{"issue":"2","key":"702_CR26","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00198-017-4270-2","volume":"29","author":"P Dunn","year":"2018","unstructured":"Dunn P, Webb D, Olenginski TP (2018) Geisinger high-risk osteoporosis clinic (HiROC): 2013-2015 FLS performance analysis. Osteoporos Int 29(2):451\u2013457. https:\/\/doi.org\/10.1007\/s00198-017-4270-2","journal-title":"Osteoporos Int"},{"issue":"11","key":"702_CR27","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1007\/s00296-011-2203-5","volume":"32","author":"TP Olenginski","year":"2012","unstructured":"Olenginski TP, Antohe JL, Sunderlin E, Harrington TM (2012) Appraising osteoporosis care gaps. Rheumatol Int 32(11):3619\u20133624. https:\/\/doi.org\/10.1007\/s00296-011-2203-5","journal-title":"Rheumatol Int"},{"issue":"3","key":"702_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11914-017-0367-y","volume":"15","author":"SM Ott","year":"2017","unstructured":"Ott SM (2017) Renal osteodystrophy-time for common nomenclature. Curr Osteoporos Rep 15(3):187\u2013193. https:\/\/doi.org\/10.1007\/s11914-017-0367-y","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"702_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.kint.2016.12.029","volume":"91","author":"FG Graciolli","year":"2017","unstructured":"Graciolli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, Sabbagh Y, Carvalho AB, Jorgetti V, Elias RM, Schiavi S, Moyses RMA (2017) The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int 91(6):1436\u20131446. https:\/\/doi.org\/10.1016\/j.kint.2016.12.029","journal-title":"Kidney Int"},{"issue":"5","key":"702_CR30","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s40620-017-0404-z","volume":"30","author":"J Bover","year":"2017","unstructured":"Bover J, Bailone L, Lopez-Baez V, Benito S, Ciceri P, Galassi A, Cozzolino M (2017) Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. J Nephrol 30(5):677\u2013687. https:\/\/doi.org\/10.1007\/s40620-017-0404-z","journal-title":"J Nephrol"},{"issue":"4","key":"702_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/mnh.0000000000000418","volume":"27","author":"C Steller Wagner Martins","year":"2018","unstructured":"Steller Wagner Martins C, Jorgetti V, Moyses RMA (2018) Time to rethink the use of bone biopsy to prevent fractures in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 27(4):243\u2013250. https:\/\/doi.org\/10.1097\/mnh.0000000000000418","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"12","key":"702_CR32","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/jbmr.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 20(12):2105\u20132115. https:\/\/doi.org\/10.1359\/jbmr.050817","journal-title":"J Bone Miner Res"},{"issue":"4","key":"702_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, Cummings SR (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503\u2013508. https:\/\/doi.org\/10.1359\/jbmr.070112","journal-title":"J Bone Miner Res"},{"issue":"9","key":"702_CR34","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239\u20132256. https:\/\/doi.org\/10.1007\/s00198-012-1964-3","journal-title":"Osteoporos Int"},{"issue":"8","key":"702_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11(8):669\u2013674. https:\/\/doi.org\/10.1007\/s001980070064","journal-title":"Osteoporos Int"},{"issue":"2","key":"702_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.ajkd.2018.08.013","volume":"73","author":"LA Inker","year":"2019","unstructured":"Inker LA, Grams ME, Levey AS, Coresh J, Cirillo M, Collins JF, Gansevoort RT, Gutierrez OM, Hamano T, Heine GH, Ishikawa S, Jee SH, Kronenberg F, Landray MJ, Miura K, Nadkarni GN, Peralta CA, Rothenbacher D, Schaeffner E, Sedaghat S, Shlipak MG, Zhang L, van Zuilen AD, Hallan SI, Kovesdy CP, Woodward M, Levin A (2019) Relationship of estimated GFR and albuminuria to concurrent laboratory abnormalities: an individual participant data meta-analysis in a global consortium. Am J Kidney Dis 73(2):206\u2013217. https:\/\/doi.org\/10.1053\/j.ajkd.2018.08.013","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"702_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385\u2013397. https:\/\/doi.org\/10.1007\/s00198-007-0543-5","journal-title":"Osteoporos Int"},{"issue":"2","key":"702_CR38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.kint.2018.09.022","volume":"95","author":"RH Whitlock","year":"2019","unstructured":"Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, Collister D, Kanis JA, Tangri N (2019) The fracture risk assessment tool (FRAX(R)) predicts fracture risk in patients with chronic kidney disease. Kidney Int 95(2):447\u2013454. https:\/\/doi.org\/10.1016\/j.kint.2018.09.022","journal-title":"Kidney Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-0702-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-020-0702-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-020-0702-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T23:19:51Z","timestamp":1620515991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-020-0702-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s11657-020-0702-2","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,9]]},"assertion":[{"value":"24 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Evans reports funding to Karolinska Institutet from Astra Zeneca and Astellas outside this work and payment for lectures (Astellas, Vifor Pharma) and advisory board (Astra Zeneca, Astellas). Dr. Grams reports funding from the National Kidney Foundation and the NIH. Dr. Inker reports funding to Tufts Medical Center for research and contracts with the NIH, NKF, Dialysis Inc., Retrophin, Omeros, and Reata Pharmaceuticals. She has consulting agreements with Tricida. Dr. Carrero reports funding to Karolinska Institutet for research from AstraZeneca, Viforpharma, Astellas, and MSD outside the submitted work. He has performed consultation for Fresenius and Baxter. All the other authors declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"69"}}